Xanthatin

Cat. No.: 0225LY-1314

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Xanthatin possesses cytotoxic and antimicrobial activities against MRSA; it shows therapeutic potential for NSCLC and melanoma by inhibiting angiogenesis and modulating the Wnt/beta-catenin pathway to stop cell proliferation.

Synonym: 26791-73-1; (-)-Xanthatin; (3aR,7S,8aS)-7-methyl-3-methylidene-6-[(E)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one; (3aR,7S,8aS)-7-Methyl-3-methylene-6-((E)-3-oxobut-1-en-1-yl)-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one; (3aR,7S,8aS)-7-methyl-3-methylidene-6-[(1E)-3-oxobut-1-en-1-yl]-2H,3H,3aH,4H,7H,8H,8aH-cyclohepta[b]furan-2-one

CAS No.: 26791-73-1

Compound CID: 5281511

Formula: C₁₅H₁₈O₃

Formula Weight: 246.3

Specification

Targets&IC50: T. b. brucei: 2.63 µg/mL (IC50); VEGFR2 kinase: 3.8 μM (IC50)

Relative Density: 1.1 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Xanthatin can be used in oncology research to explore the inhibition of tumor angiogenesis and the suppression of pro-inflammatory transcription factors.